<SEC-DOCUMENT>0001193125-20-034312.txt : 20200331
<SEC-HEADER>0001193125-20-034312.hdr.sgml : 20200331
<ACCEPTANCE-DATETIME>20200213080603
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-20-034312
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20200213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORGANOVO HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001497253
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				271488943
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		440 STEVENS AVENUE, SUITE 200
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075
		BUSINESS PHONE:		858-224-1000

	MAIL ADDRESS:	
		STREET 1:		440 STEVENS AVENUE, SUITE 200
		CITY:			SOLANA BEACH
		STATE:			CA
		ZIP:			92075

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REAL ESTATE RESTORATION & RENTAL, INC.
		DATE OF NAME CHANGE:	20100722
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g855065g23x86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">February 13, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B><I>VIA
EDGAR AND OVERNIGHT COURIER </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">100 F. Street, N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">Attention:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Ada D. Sarmento </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Mary Beth Breslin </P></TD></TR></TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Organovo Holdings, Inc. </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment No.&nbsp;1 to Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT>
</B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Filed January&nbsp;29, 2020 </B></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;333-235683</FONT> </B></P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Dear Mses. Sarmento and Breslin: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">On behalf of Organovo Holdings, Inc. (the &#147;Company&#148; or &#147;Organovo&#148;), we submit this letter in response to
comments from the staff (the &#147;Staff&#148;) of the Securities and Exchange Commission (the &#147;Commission&#148;) received by letter dated February&nbsp;7, 2020 relating to the Company&#146;s above-referenced Amendment No.&nbsp;1 to
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> (the &#147;Form <FONT STYLE="white-space:nowrap">S-4/A&#148;).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">On behalf of the Company, we are also submitting via EDGAR a revised Form <FONT STYLE="white-space:nowrap">S-4/A</FONT> (the
&#147;Revised Form <FONT STYLE="white-space:nowrap">S-4/A&#148;),</FONT> and for the convenience of the Staff, we are providing to the Staff by courier copies of this letter and marked copies of the Revised Form
<FONT STYLE="white-space:nowrap">S-4/A</FONT> against the Form <FONT STYLE="white-space:nowrap">S-4/A.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In this
letter, we have recited the written comments from the Staff in italicized, bold type and have followed each comment with the Company&#146;s response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><U>Amendment No.&nbsp;1 to Form <FONT STYLE="white-space:nowrap">S-4</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><U>Background of the Merger, page 96 </U></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We note your revised disclosure in response to our prior comment 4.
Please disclose how the Organovo special committee considered the fact that Tarveda will still require substantial </I></B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">February 13, 2020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>
additional funding to finance its operations. For example, in this regard, it appears this was a consideration in evaluating the proposal from Company L described on pages <FONT
STYLE="white-space:nowrap">111-12.</FONT> </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 1: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We acknowledge the Staff&#146;s comment and have revised the disclosure as requested on pages 109 and 110 of the Revised Form <FONT
STYLE="white-space:nowrap">S-4/A</FONT><I> </I>to<I> </I>disclose how the Organovo special committee considered the fact that Tarveda will still require substantial additional funding to finance its operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Tarveda&#146;s Product Pipeline, page 200 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><B><I>We note your response to our prior comment 9. We believe that
it is premature to include the two discovery stage programs in your pipeline table, particularly where there is minimal discussion of these programs in your disclosure. Please remove these programs from the table. We do not object to a discussion of
each program below the table</I></B><I>. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 2: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We acknowledge the Staff&#146;s comment and have revised the disclosure as requested on page 199 of the Revised Form <FONT
STYLE="white-space:nowrap">S-4/A</FONT> to remove these programs from the pipeline table. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><I>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><B><I>Please revise the pipeline table to reflect that you have yet
to complete the Phase 1 portion of your Phase 1/2a trial for <FONT STYLE="white-space:nowrap">PEN-866</FONT> by shortening the line accordingly</I></B><I>. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 3: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We acknowledge the Staff&#146;s comment and have revised the pipeline table on page 199 of the Revised Form <FONT
STYLE="white-space:nowrap">S-4/A</FONT> to shorten the line for the Phase 1/2a trial for <FONT STYLE="white-space:nowrap">PEN-866.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Madrigal Pharmaceuticals, Inc. License Agreement, page 204 </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We note your disclosure that the royalties are payable, on a product
by product and country by country basis, until the latest to occur of expiration of the last to expire valid claim covering such product in such country or expiration of regulatory exclusivity for such product in such country. Please revise your
description of this agreement to clarify when the royalty term ends. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 4: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We respectfully acknowledge the Staff&#146;s comment and supplementally advise the Staff that, consistent with the disclosures
beginning on page 204 of the Revised Form <FONT STYLE="white-space:nowrap">S-4/A,</FONT> the royalty term is a function of (a)&nbsp;patent protection in a particular country and (b)&nbsp;regulatory exclusivity in such country. Accordingly, until
such time Tarveda has an approved product in a particular country, it cannot with any certainty know when regulatory exclusivity will expire, or if such exclusivity will be later than the expiration of valid claims under the patents licensed from
Madrigal. While we have revised the disclosure on pages 204 of the Revised Form <FONT STYLE="white-space:nowrap">S-4/A</FONT> to add additional language regarding the patent protection (including the meaning of &#147;valid claim&#148;) and
Tarveda&#146;s current expectations of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">February 13, 2020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"> Page
 3
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify">
the minimum duration of such royalty term based on current valid claims in specific jurisdictions to address the Staff&#146;s comment regarding the end of the royalty term, we respectfully advise
the Staff that Tarveda cannot, at this time, state with any certainty when the royalty term, if any, would end. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Unaudited Pro Forma
Combined Financial Statements </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><U>Note 4. Adjustments to Unaudited Pro Forma Combined Balance Sheet as of
September</U><U></U><U>&nbsp;30, 2019, page 270 </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We note your
response to our prior comment 14. Please tell us how you reflect the issuance of Organovo common shares to effect the reverse merger in the pro forma balance sheet. In this regard, pro forma adjustment F appears to reflect the conversion of
Tarveda&#146;s outstanding preferred stock into common stock, but it is not clear whether this adjustment also reflects the exchange of outstanding Tarveda common stock into Organovo common stock based on the exchange ratio set forth in the Merger
Agreement. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 5: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">In response to the Staff&#146;s comment, we have revised the unaudited pro forma balance sheet and related disclosure on pages
267 and 268, footnote 4, of the Revised Form <FONT STYLE="white-space:nowrap">S-4/A</FONT> to reflect the exchange of outstanding Tarveda common stock into Organovo common stock based on the preliminary, assumed exchange ratio, calculated as
described in the notes to the unaudited pro forma combined financial statements using the exchange ratio formula set forth in the Merger Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B><I>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a related matter, pro forma adjustment F also includes the
elimination of historical Organovo equity. Please reconcile for us the adjustment to remove $273.2&nbsp;million in APIC to Organovo&#146;s historical APIC balance of $304.3&nbsp;million as of September&nbsp;30, 2019. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><B>RESPONSE TO COMMENT 6: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">We acknowledge the Staff&#146;s comment and supplementally advise the Staff that we have updated the pro forma financial
statements to the most recent balance sheet date, December&nbsp;31, 2019. In addition, we have revised the disclosure table for pro forma adjustment E on pages 267 and 268, footnote 4, of the Revised Form
<FONT STYLE="white-space:nowrap">S-4/A</FONT> to clearly present the components of the adjustments to APIC. In the Revised Form <FONT STYLE="white-space:nowrap">S-4/A,</FONT> the elimination of Organovo&#146;s historical APIC balance is offset by
the effect of the reverse recapitalization on APIC. In the Revised Form <FONT STYLE="white-space:nowrap">S-4/A&#146;s</FONT> unaudited pro forma combined financial statements, we have presented separately the a) elimination of Organovo&#146;s
historical APIC balance of $304.3&nbsp;million and b) the effect of the reverse recapitalization on APIC of $28.8&nbsp;million, which is the net carrying value of Organovo as of December&nbsp;31, 2019 less $0.1&nbsp;million recorded for the par
value of Organovo common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><I>[Remainder of page intentionally left blank.] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">February 13, 2020 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"> Page
 4
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:12pt; font-family:Times New Roman" ALIGN="justify">Please do not hesitate to contact Jeff Thacker at <FONT STYLE="white-space:nowrap">(858)&nbsp;436-8064</FONT> or
jthacker@gunder.com, if you have any questions or would like additional information regarding this matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">GUNDERSON DETTMER STOUGH </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman">VILLENEUVE FRANKLIN&nbsp;&amp;
HACHIGIAN, LLP </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt">


<TR>

<TD WIDTH="9%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:12pt; font-family:Times New Roman">/s/ Jeffrey C. Thacker</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey C. Thacker</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Craig Kussman </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Taylor Crouch </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Jennifer Bush </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Organovo Holdings, Inc.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Jeffrey R. Vetter </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Ryan J. Gunderson </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Gunderson Dettmer Stough Villeneuve Franklin</B><B></B><B>&nbsp;&amp; Hachigian, LLP</B>
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Andrew J. Fromkin </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;<B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Tarveda Therapeutics, Inc.</B> </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Miguel J. Vega </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left">Marianne C. Sarrazin </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman; " ALIGN="left"><B>Cooley LLP</B> </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g855065g23x86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g855065g23x86.jpg
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M+W)D9CI21$8^(#PO>#IX;7!M971A/B \/WAP86-K970@96YD/2)R(C\^_^X
M#D%D;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$"
M 0$" @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,# P,#_\  $0@ L0,T P$1  (1 0,1 ?_$ )T  0 !!0$! 0$!
M           ! @8'" D%! H#"P$! 0$! 0$               $" P0%$
M!@(" 0($!0$%!P0# 0   0,$!08"!Q$((3$201,4"5%A<2(5%H&1P2,7\*'1
MX3(8"K'Q0B12,R49$0$  @$# P,$ 00# 0       1$"(3$206$#47$$@9&A
M$R+PL<'1X3(C,__:  P# 0 "$0,1 #\ _?P
M
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MV\<EX/U_'R?'P$%8H
M
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MS_O&_JPD4
M
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M_P#UX\>5%L[\8^W\N.>?\>1:+5
M
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MH
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MEQ8CTV2_NZ+\'QZ^>/R]?[ANM*9T2*@
M
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MZ_']?U%Z,I%   /0$F: 4
M
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MH520
M
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M %0      @L2+TY\@''GGSR D
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M_C^)\F)>HJ/R1D1\&*)]
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M;Z0VC\_B7'^']XK/]V.MNVU6A:KV9>D?*E+H%RM26/!&9K5^NR$LCQR61?\
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MKF@3E'/V<%^W'43U&WPT!ESX, ]/!
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M4R/(\N2*QM0W5(S/U+CGT(_7\^1L2
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M^/'X? 6J%0
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M'!\\\^./0!(".///)_H"4D%  !'!\\\_V '!?@0"0#_     !!&1^2#82
M!Z     *#QY/DCX_V_4!6
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MZB5U$BAZ^H  I]#X(N.?4R$KK"6J%4
M
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MY]/45E(
M
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M3SXYX_L_/\.?3U&KT8I(T@
M
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MRP6S39,\#))(L\LC]V>1Y#6D)>C9CGQZ'Z<^WX_IP-(D5
M
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M,3-N3A))4T\U%>/>>XN^[,[.@OPY\<\>OP_X\#IK2*AM
M
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M'C_'QQ^OKZ"TS>JH:0
M
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M+Y9G[OV\$86E2V]X+CCX<<<?D*)
M
M                         $<>OG_D D  ?*[-P35WDVP34<8MULFJ:F1X
M)J+$ED:6"N9%D>.&:O!&9>A>1F8F?98W<:>F5EM*G9%!O0=3[?TM4[/5=@3W
M;34=KJ-IB-':_P!V-Y:/_IJ:TK/VJ/9,W\G>5LWSJ1P@\U8MTW/!QF2:_NQ'
M/KV=)_*R]<Z2G-B:9Z(:TN5-LS&,E'W<N$NJ4E7Y5HI4T+75=H,X&2F2=-$L
MX(\Y60:K,E'!)_-5-/Y?NRRQYSQTB/=9F(F96=KV+W=+]9=MWNYZPOCW8.M^
M^FMMIW"J)5>6_J:[PFGE]:P5VL=+A7+=NYL;>6:UMY*,_I/FXO,2/%$\C/$(
MB:^W^65VJ;#V_?=)_<!6UJKV0ME?W#=]=ZYZZ%O*G["B7D$6VH2.KU]7K\!8
MZ]!6&&UK3Y.<=JKY?3X)M6S4_P#,YQ(QJMTO5_7'6O8+5](^X1I[94!49Y;9
MO4AE=J(\T53+XUH[B;KFMIO3#VJL&=B<3SYS?7\;6X=SDV;N,LW)9EG@D1\A
M$5I*WU9LE.D]8IG1[=D/J&L7><V]M_0-<:S"MVO-NOETG92LUI-]$4AK*7F7
ME9"&8,W.:Z+2,2S0;)++>W'#'(Q:^Y>KQ:1;YOL)L?L+N>M:WVM5J;#]'6^E
MVY;'UU9:+,SFR\G=VL\_78>"LK!G*S'].DX;ME%T4<VJ[E;VHJ*EP9NNOHO3
MO;%_571+S2C[-K"P>SW#3:'VVH67M!W]U<[R\AMI1;ARS4I,',VTG\E3FRC*
M244*KMET&V*F)9)M<3QY$B*]Z69O?U9C^U;'ZBA-3PL/3_\ N6C]CQFL-;H;
M4B=Y->P+*LPT\A&$W>QE C=P,VE.C6[>5Q7PR1KN&*>"9XED18GASK&&9G[.
MMOCCX\>OQYX]?3U&ZAA(J
M
M                      "./7\P%)IXGQR1&1<<$?DBX\%P1\ECX_ 2EM/!
M>X_V^I%R?P/\O[ J++/;CZF1&?KR?DR\\EP9^G!A4(<<9<\<F?CG\"+T_P#4
M*$?+P+C]N/!'SB7!<8G^.)>A'^?J%"3(N2\>I\G^O_,*6T'ACS[BQ(\O@9^3
M_3D_/ 47*2(CQ\XEY,S,B+CSSSS^O/GG\0I$<<\%QX(^3+/G+\RX,S/T,!6*
M
M
A        D[(Q]"_06=R$B*C+T/\ 06-TE(A&P"@  __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
